Beta-cell Responsiveness to the Incretin Hormones (Aim1)

Beta-cell Responsiveness to the Incretin Hormones (Aim1)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance. This study includes 3 or 4 visits.

Eligibility and criteria
IRB Number:
13-010240
Eligible age range:
18 years - 99 years
Clinical trial phase:
N/A
Official title:
Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis (Penn IRB of record, # 817585)

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.